Cargando…
Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation
With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327983/ https://www.ncbi.nlm.nih.gov/pubmed/30734612 http://dx.doi.org/10.1080/14756366.2018.1480614 |
_version_ | 1783386575902605312 |
---|---|
author | Xu, Xi Ren, Jie Ma, Yinghe Liu, Hongting Rong, Quanjin Feng, Yifan Wang, Yameng Cheng, Yu Ge, Ruijia Li, Zhiyu Bian, Jinlei |
author_facet | Xu, Xi Ren, Jie Ma, Yinghe Liu, Hongting Rong, Quanjin Feng, Yifan Wang, Yameng Cheng, Yu Ge, Ruijia Li, Zhiyu Bian, Jinlei |
author_sort | Xu, Xi |
collection | PubMed |
description | With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment. |
format | Online Article Text |
id | pubmed-6327983 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-63279832019-01-16 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation Xu, Xi Ren, Jie Ma, Yinghe Liu, Hongting Rong, Quanjin Feng, Yifan Wang, Yameng Cheng, Yu Ge, Ruijia Li, Zhiyu Bian, Jinlei J Enzyme Inhib Med Chem Research Paper With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment. Taylor & Francis 2019-01-02 /pmc/articles/PMC6327983/ /pubmed/30734612 http://dx.doi.org/10.1080/14756366.2018.1480614 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Xu, Xi Ren, Jie Ma, Yinghe Liu, Hongting Rong, Quanjin Feng, Yifan Wang, Yameng Cheng, Yu Ge, Ruijia Li, Zhiyu Bian, Jinlei Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title | Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title_full | Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title_fullStr | Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title_full_unstemmed | Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title_short | Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation |
title_sort | discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (ido1) inhibitors through virtual screening and preliminary hit optimisation |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327983/ https://www.ncbi.nlm.nih.gov/pubmed/30734612 http://dx.doi.org/10.1080/14756366.2018.1480614 |
work_keys_str_mv | AT xuxi discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT renjie discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT mayinghe discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT liuhongting discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT rongquanjin discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT fengyifan discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT wangyameng discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT chengyu discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT geruijia discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT lizhiyu discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation AT bianjinlei discoveryofcyanopyridinescaffoldasnovelindoleamine23dioxygenase1ido1inhibitorsthroughvirtualscreeningandpreliminaryhitoptimisation |